35228 Federal Register / Vol. 87, No. 111 / Thursday, June 9, 2022 / Notices 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel PAR–21–356 

Swine Center Review. 

Date: June 30, 2022. 

Time: 11:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Katherine M Malinda, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4140, 

MSC 7814, Bethesda, MD 20892 (301) 435– 

0912, katherine.malinda@nih.gov. 

Name of Committee: Population Sciences 

and Epidemiology Integrated Review Group 

Infectious Diseases, Reproductive Health, 

Asthma and Pulmonary Conditions Study 

Section. 

Date: July 7–8, 2022. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting), 

Contact Person: Mohammed F A 

Elfaramawi, Ph.D., MD Scientific Review 

Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 1007F, Bethesda, MD 20892, 

(301) 402–6746, elfaramawimf@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Fellowships: 

Risks, Prevention and Health Behavior. 

Date: July 7–8, 2022. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Martha M Faraday, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3110, 

MSC 7808, Bethesda, MD 20892, (301) 435– 

3575, faradaym@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Small 

Business: Disease Management, Risk 

Prevention and Health Behavior Change. 

Date: July 7–8, 2022. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Izabella Zandberg, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–0359, izabella.zandberg@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel RFA–NR– 

22–002: Advancing Integrated Models (AIM) 

of Care to Improve Maternal Health 

Outcomes among Women Who Experience 

Persistent Disparities. 

Date: July 12, 2022. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Hoa Thi Vo, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1002B2, 

Bethesda, MD 20892, (301) 594–0776, voht@

csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Member 

Conflict: Topics in Vaccines Against 

Microbial Diseases. 

Date: July 15, 2022. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Liangbiao Zheng, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3202, 

MSC 7808, Bethesda, MD 20892 301–996– 

5819, zhengli@csr.nih.gov. 

Name of Committee: Infectious Diseases 

and Immunology A Integrated Review Group 

HIV Molecular Virology, Cell Biology, and 

Drug Development Study Section. 

Date: July 18–19, 2022. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Kenneth A Roebuck, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5214, 

MSC 7852, Bethesda, MD 20892, (301) 435– 

1166, roebuckk@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review, Special Emphasis Panel Small 

Business: Immune responses and Vaccines to 

Microbial Infections. 

Date: July 19, 2022. 

Time: 9:00 a.m. to 9:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Subhamoy Pal, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–0926, subhamoy.pal@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Fellowships: 

Physiology and Pathobiology of 

Cardiovascular and Respiratory Systems. 

Date: July 20–21, 2022. 

Time: 9:00 a.m. to 9:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Kimm Hamann, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4118A, 

MSC 7814 Bethesda, MD 20892, 301–435– 

5575, hamannkj@csr.nih.gov. 

Name of Committee: Infectious Diseases 

and Immunology B Integrated Review Group 

HIV Coinfections and HIV Associated 

Cancers Study Section. 

Date: July 21, 2022. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Audrey O Lau, MPH, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–4088, audrey.lau@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: June 3, 2022. 

Victoria E. Townsend, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12444 Filed 6–8–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Dental & 

Craniofacial Research; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Dental and Craniofacial Research Special 

Emphasis Panel; Prevention of Opioid Drug 

Misuse and Abuse. 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 111 / Thursday, June 9, 2022 / Notices 35229 

Date: July 22, 2022. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Dental and 

Craniofacial Research, 6701 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Yun Mei, MD, Scientific 

Review Officer, Scientific Review Branch, 

National Institute of Dental and Craniofacial 

Research, National Institutes of Health, 6701 

Democracy Boulevard, Suite #670, Bethesda, 

MD 20892, (301) 827–4639, yun.mei@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.121, Oral Diseases and 

Disorders Research, National Institutes of 

Health, HHS) 

Dated: June 6, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12465 Filed 6–8–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health And Human 

Development; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; Chemical Synthesis 

Facility. 

Date: July 22, 2022. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development, National Institutes of Health, 

6710B Rockledge Drive, Room 2131D, 

Bethesda, MD 20892 (Video Assisted 

Meeting). 

Contact Person: Sathasiva B. Kandasamy, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development, National Institutes of 

Health, 6710B Rockledge Drive, Room 2131D, 

Bethesda, MD 20892, (301) 435–6680, 

skandasa@mail.nih.gov. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; Biomedical Assay 

Laboratory. 

Date: July 29, 2022. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development, National Institutes of Health, 

6710B Rockledge Drive, Room 2131D, 

Bethesda, MD 20892 (Video Assisted 

Meeting). 

Contact Person: Sathasiva B. Kandasamy, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development, National Institutes of 

Health, 6710B Rockledge Drive, Room 2131D, 

Bethesda, MD 20892, (301) 435–6680, 

skandasa@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.865, Research for Mothers 

and Children, National Institutes of Health, 

HHS) 

Dated: June 3, 2022. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12419 Filed 6–8–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID FEMA–2022–0002; Internal 

Agency Docket No. FEMA–B–2242] 

Proposed Flood Hazard 

Determinations 

AGENCY: Federal Emergency 

Management Agency, Department of 

Homeland Security. 

ACTION: Notice. 

SUMMARY: Comments are requested on 

proposed flood hazard determinations, 

which may include additions or 

modifications of any Base Flood 

Elevation (BFE), base flood depth, 

Special Flood Hazard Area (SFHA) 

boundary or zone designation, or 

regulatory floodway on the Flood 

Insurance Rate Maps (FIRMs), and 

where applicable, in the supporting 

Flood Insurance Study (FIS) reports for 

the communities listed in the table 

below. The purpose of this notice is to 

seek general information and comment 

regarding the preliminary FIRM, and 

where applicable, the FIS report that the 

Federal Emergency Management Agency 

(FEMA) has provided to the affected 

communities. The FIRM and FIS report 

are the basis of the floodplain 

management measures that the 

community is required either to adopt 

or to show evidence of having in effect 

in order to qualify or remain qualified 

for participation in the National Flood 

Insurance Program (NFIP). 

DATES: Comments are to be submitted 

on or before September 7, 2022. 

ADDRESSES: The Preliminary FIRM, and 

where applicable, the FIS report for 

each community are available for 

inspection at both the online location 

https://hazards.fema.gov/femaportal/ 

prelimdownload and the respective 

Community Map Repository address 

listed in the tables below. Additionally, 

the current effective FIRM and FIS 

report for each community are 

accessible online through the FEMA 

Map Service Center at https:// 

msc.fema.gov for comparison. 

You may submit comments, identified 

by Docket No. FEMA–B–2242, to Rick 

Sacbibit, Chief, Engineering Services 

Branch, Federal Insurance and 

Mitigation Administration, FEMA, 400 

C Street SW, Washington, DC 20472, 

(202) 646–7659, or (email) 

patrick.sacbibit@fema.dhs.gov. 

FOR FURTHER INFORMATION CONTACT: Rick 

Sacbibit, Chief, Engineering Services 

Branch, Federal Insurance and 

Mitigation Administration, FEMA, 400 

C Street SW, Washington, DC 20472, 

(202) 646–7659, or (email) 

patrick.sacbibit@fema.dhs.gov; or visit 

the FEMA Mapping and Insurance 

eXchange (FMIX) online at https:// 

www.floodmaps.fema.gov/fhm/fmx_

main.html. 

SUPPLEMENTARY INFORMATION: FEMA 

proposes to make flood hazard 

determinations for each community 

listed below, in accordance with section 

110 of the Flood Disaster Protection Act 

of 1973, 42 U.S.C. 4104, and 44 CFR 

67.4(a). 

These proposed flood hazard 

determinations, together with the 

floodplain management criteria required 

by 44 CFR 60.3, are the minimum that 

are required. They should not be 

construed to mean that the community 

must change any existing ordinances 

that are more stringent in their 

floodplain management requirements. 

The community may at any time enact 

stricter requirements of its own or 

pursuant to policies established by other 

Federal, State, or regional entities. 

These flood hazard determinations are 

used to meet the floodplain 

management requirements of the NFIP. 

The communities affected by the 

flood hazard determinations are 


lotter on DSK11XQN23PROD with NOTICES1